<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21383" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ethambutol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Nick</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hoang</given-names>
          </name>
          <aff>NOVA Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nick Lee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hoang Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21383.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ethambutol is a bacteriostatic drug that inhibits cell wall synthesis and is used to manage and treat tuberculosis (TB). The mechanism of action, dosing considerations, pharmacokinetics, adverse event profiles, contraindications, boxed warnings, and monitoring strategies are highlighted within a multi-drug&#x000a0;treatment. In particular, the severe adverse drug reaction relating to optic neuropathy is discussed, with relevant interventions mentioned.&#x000a0;New drugs like bedaquiline promise to improve TB&#x000a0;outcomes, but addressing pharmacy challenges and ensuring interprofessional collaboration remains crucial for effective patient management with ethambutol therapy. Given the emergence of ethambutol-resistant&#x000a0;TB strains, the emphasis on contraindicated single regimen use is important. This activity will highlight other key factors, such as off-label uses, dosing, and monitoring, pertinent to healthcare team members treating patients with tuberculosis and related conditions. The interprofessional team, including infectious disease specialists or ophthalmologists in complicated cases, is equipped with comprehensive knowledge to enhance patient care during therapy with ethambutol.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ethambutol in comparison to other medications for tuberculosis.</p></list-item><list-item><p>Evaluate&#x000a0;the potential adverse effects of ethambutol with emphasis on optic neuropathy.</p></list-item><list-item><p>Determine&#x000a0;the appropriate monitoring for patients&#x000a0;undergoing therapy with ethambutol.</p></list-item><list-item><p>Strategize effective collaboration among interprofessional team members to improve treatment efficacy for patients who benefit from treatment with ethambutol.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21383&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21383">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21383.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ethambutol has been&#x000a0;utilized to treat tuberculosis (TB) since the 1960s. The original formulation of&#x000a0;ethambutol was a racemic mixture of&#x000a0;the L and D forms. The D form of ethambutol was known for its therapeutic effect; however, the L form was known for&#x000a0;toxicity and, hence, discontinued.<xref ref-type="bibr" rid="article-21383.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Ethambutol is used for the treatment of pulmonary tuberculosis.&#x000a0;The medication should not be used&#x000a0;as a single regimen but with at least&#x000a0;1 antitubercular drug, such as isoniazid (INH).&#x000a0;Ethambutol is effective against <italic toggle="yes">Mycobacterium tuberculosis</italic> strains&#x000a0;but&#x000a0;less effective against viruses, fungi, or other bacteria.&#x000a0;Antitubercular medications used with&#x000a0;ethambutol include cycloserine, ethionamide, pyrazinamide, viomycin, INH, aminosalicylic acid, and streptomycin.<xref ref-type="bibr" rid="article-21383.r2">[2]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The American Thoracic Society/European Society of Clinical Microbiology and Infectious Diseases/European Respiratory Society/Infectious Diseases Society of America guideline for nontuberculous mycobacterial pulmonary disease endorses ethambutol for&#x000a0;<italic toggle="yes">Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi.</italic><xref ref-type="bibr" rid="article-21383.r3">[3]</xref>&#x000a0;Few imaging techniques can directly visualize tuberculosis in the body. Although not widely documented, technetium-99m ethambutol scintigraphy is emerging as a promising method. In a recent case, a patient with an iliopsoas abscess demonstrated increased uptake on Tc-99m ethambutol scintigraphy, later confirmed tubercular through pus analysis. This underscores the potential of Tc-99m ethambutol scintigraphy as a sensitive&#x000a0;tool&#x000a0;for detecting tubercular lesions, offering valuable insights for treatment and monitoring.<xref ref-type="bibr" rid="article-21383.r4">[4]</xref></p>
      </sec>
      <sec id="article-21383.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ethambutol is&#x000a0;1 of the first lines of treatment for TB, along with rifampicin, INH, and pyrazinamide. Ethambutol is considered a bacteriostatic drug, interfering with the biosynthesis of arabinogalactan in the cell wall, halting multiplying bacilli.<xref ref-type="bibr" rid="article-21383.r5">[5]</xref>&#x000a0;However, the underlying molecular mechanisms remain unclear.<xref ref-type="bibr" rid="article-21383.r6">[6]</xref></p>
        <p>Researchers speculate that ethambutol has synergistic effects with INH against <italic toggle="yes">Mycobacterium tuberculosis&#x000a0;</italic>through a transcriptional repressor of the <italic toggle="yes">inhA</italic> gene, a targeted gene by INH that encodes for an enoyl-acyl carrier protein reductase, which is necessary for bacterial cell wall integrity. The results of a study indicate that ethambutol binds to a TetR transcriptional regulator that enhances the INH sensitivity of the <italic toggle="yes">inhA</italic> gene. As a result, the&#x000a0;bactericidal&#x000a0;effect of INH is increased.<xref ref-type="bibr" rid="article-21383.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Ethambutol achieves peak serum concentrations within 2 to 4 hours post-administration. Upon daily administration at this dosage over prolonged periods, serum levels remain consistent.</p>
        <p><bold>Distribution:</bold> The drug's distribution is widespread, with erythrocyte concentrations approximately twice that of plasma. Ethambutol hydrochloride diffuses readily into actively growing mycobacterium cells, contributing to therapeutic efficacy.</p>
        <p><bold>Metabolism:</bold> The metabolism of ethambutol to an aldehyde intermediate and dicarboxylic acid is catalyzed by the alcohol dehydrogenase enzyme.</p>
        <p><bold>Excretion:</bold> Ethambutol&#x000a0;is eliminated primarily via renal excretion, with a smaller fraction excreted in the feces. Patients with renal insufficiency may exhibit marked drug accumulation due to impaired clearance mechanisms.<xref ref-type="bibr" rid="article-21383.r8">[8]</xref></p>
      </sec>
      <sec id="article-21383.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Ethambutol can be administered orally and in tablet form in 400 and 100 mg doses. It should not be used stand-alone in initial treatment or re-treatment; it should be used in conjunction with another antitubercular drug.&#x000a0;Current first-line therapy for tuberculosis is a quadruple therapy of INH, rifampicin, pyrazinamide, and ethambutol for&#x000a0;2 months, followed by a 4-month continuation of INH, rifampicin, and ethambutol.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Initial treatment</bold>
</p>
        <p>Initial treatment for patients who have not received previous tuberculosis therapy should be administered with 15 mg/kg of body weight every 24 hours.</p>
        <p>
<bold>Re-treatment</bold>
</p>
        <p>Multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB) is a global issue.<xref ref-type="bibr" rid="article-21383.r9">[9]</xref> For&#x000a0;patients with a history of previous tuberculosis treatment, the recommended dosage of ethambutol is 25 mg/kg administered orally daily. After 60 days of continuous therapy, the dosage should be reduced to 15 mg/kg administered orally once daily. The dosages for ethambutol, recommended by the American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for drug-susceptible tuberculosis, are outlined below.</p>
        <p>
<bold>Daily regimen</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For individuals weighing 40 to 55 kg:&#x000a0;800 mg (14.5 to 20 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 56 to 75 kg:&#x000a0;1200 mg (16 to 21.4 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 76 to 90 kg:&#x000a0;1600 mg (17.8 to 21.1 mg/kg)</p>
          </list-item>
        </list>
        <p>
<bold>Thrice weekly regimen</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For individuals weighing 40 to 55 kg:&#x000a0;1200 mg (21.8 to 30 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 56 to 75 kg:&#x000a0;2000 mg (26.7 to 35.7 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 76 to 90 kg:&#x000a0;2400 mg (26.7 to 31.6 mg/kg)</p>
          </list-item>
        </list>
        <p>
<bold>Twice weekly regimen</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For individuals weighing 40 to 55 kg:&#x000a0;2000 mg (36.4 to 50 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 56 to 75 kg:&#x000a0;2800 mg (37.3 to 50 mg/kg)</p>
          </list-item>
          <list-item>
            <p>For individuals weighing 76 to 90 kg:&#x000a0;4000 mg (44.4 to 52.6 mg/kg)</p>
          </list-item>
        </list>
        <p>These dosages are calculated based on estimated lean body weight and are suitable for patients with normal renal function.<xref ref-type="bibr" rid="article-21383.r10">[10]</xref>&#x000a0;</p>
        <p>Only&#x000a0;1 reported re-treatment with ethambutol was documented in a patient who previously recovered from ethambutol-induced optic neuropathy. The patient's initial treatment consisted of 22 mg/kg/day of ethambutol with rifampicin, clarithromycin, and ciprofloxacin, which eventually developed into ethambutol-induced optic neuropathy. After&#x000a0;clinicians&#x000a0;discontinued ethambutol, her visual acuity recovered while she continued her regimen. However,&#x000a0;10 years later, the patient was diagnosed with tuberculosis again. The patient was treated with rifampicin, clarithromycin, and ethambutol at 25 mg/kg/day&#x000a0;3 days a week. With the supplementation of copper at 2 mg daily, the patient did not show significant signs of visual change after a 14-month course regimen.<xref ref-type="bibr" rid="article-21383.r11">[11]</xref>&#x000a0;The results of recent&#x000a0;studies have assessed the administration of a dry powder inhaler using ethambutol-loaded solid lipid nanoparticles. The&#x000a0;dry powder inhaler&#x000a0;formulations consisted of spray-drying ethambutol-loaded&#x000a0;solid lipid nanoparticles with and without mannitol. The encapsulation efficiency was higher than 98%, and the particle size was sub-100 nm. Results have shown that dry powder inhalers using ethambutol-loaded solid lipid nanoparticles have a high potential for the direct treatment of TB.<xref ref-type="bibr" rid="article-21383.r12">[12]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Hepatotoxicity, including instances of liver damage leading to fatalities, has been reported with the use of ethambutol. Conducting baseline liver function assessments and monitoring hepatic function throughout treatment is necessary.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;To mitigate the risk of toxicity, the dosing regimen for ethambutol must be adjusted in patients with hemodialysis or creatinine clearance below 30 mL/min. Ethambutol should be administered&#x000a0;3 times a week instead of daily.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Ethambutol&#x000a0;does not seem to have a teratogenic effect on pregnant women.<xref ref-type="bibr" rid="article-21383.r13">[13]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Limited evidence suggests that maternal intake of ethambutol&#x000a0;of 15 mg/kg daily results in minimal levels&#x000a0;in the&#x000a0;breast milk, posing low risk to infants. The&#x000a0;CDC advises against discouraging breastfeeding in women&#x000a0;being treated with ethambutol.<xref ref-type="bibr" rid="article-21383.r14">[14]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Ethambutol is not recommended for use in children under 13 due to the lack of established safety parameters.&#x000a0;Per IDSA/CDC/ATS guidelines, the pediatric dose for ethambutol ranges from 15 to 25 mg/kg.<xref ref-type="bibr" rid="article-21383.r2">[2]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Limited data on the use of ethambutol in older patients&#x000a0;suggests comparable safety and tolerability to adults.&#x000a0;Assessing renal and hepatic function in older patients is necessary due to age-related changes that can impact the metabolism and excretion of medications.</p>
      </sec>
      <sec id="article-21383.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Loss of Visual Acuity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Optic neuropathy/optic neuritis/retrobulbar neuritis
<list list-type="bullet"><list-item><p>Decreased visual acuity</p></list-item><list-item><p>Scotoma</p></list-item><list-item><p>Color blindness</p></list-item><list-item><p>Visual field defect</p></list-item><list-item><p>Blurred vision</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Numbness and tingling of extremities due to peripheral neuritis</p>
          </list-item>
          <list-item>
            <p>Mental confusion, disorientation, and possible hallucinations</p>
          </list-item>
          <list-item>
            <p>Psychosis&#x000a0;<xref ref-type="bibr" rid="article-21383.r15">[15]</xref><xref ref-type="bibr" rid="article-21383.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>Patients with&#x000a0;impaired renal function from renal tuberculosis may be more susceptible to ethambutol-induced optic neuropathy; this may be due to dependency on the kidney for excretion.<xref ref-type="bibr" rid="article-21383.r1">[1]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Coadministration of ethambutol with aluminum hydroxide-containing antacids in patients with tuberculosis reduced mean serum concentrations and urinary excretion of ethambutol.<xref ref-type="bibr" rid="article-21383.r17">[17]</xref>&#x000a0;Avoid concurrent use of ethambutol with these antacids for at least 4 hours after administration.&#x000a0;A recent study found that the effectiveness of ethambutol against tuberculosis was negatively affected by metformin and rosiglitazone. Combining these drugs could harm tuberculosis treatment, especially during the initial phase, as ethambutol is crucial. Therefore,&#x000a0;combined use is not advised in patients with tuberculosis receiving Directly Observed Therapy (DOT). Further research is needed to validate these findings.<xref ref-type="bibr" rid="article-21383.r18">[18]</xref></p>
      </sec>
      <sec id="article-21383.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients need screening for contraindications to ethambutol. These&#x000a0;contraindications would include patients incapable of noting visual symptoms, such as those with dementia, mental retardation, and children due to ethambutol-induced optic neuropathy. Other&#x000a0;contraindications&#x000a0;are patients with pre-existing ophthalmological diseases due to the&#x000a0;ocular toxicity of ethambutol.<xref ref-type="bibr" rid="article-21383.r1">[1]</xref>&#x000a0;Contraindications also include hypersensitivity&#x000a0;to ethambutol in patients.</p>
      </sec>
      <sec id="article-21383.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>A dosing regimen of a daily dose of 25 mg/kg of body weight of ethambutol reaches a therapeutic range of 2 to 6 mcg/mL in serum 2 hours after administration.<xref ref-type="bibr" rid="article-21383.r19">[19]</xref> Serum levels of&#x000a0;ethambutol&#x000a0;decrease to undetectable levels by 24 hours, except for some patients with impaired renal function. Ethambutol may cause ocular toxicity, which may be related to the dose and duration of the treatment. If signs indicate such an effect, immediate discontinuation of the drug is required. However, reports of cases of irreversible blindness exist. Due to the adverse effect of ethambutol-associated optic neuropathy, visual acuity tests such as baseline visual acuity, color vision, and a Humphrey visual field should be performed periodically when administering&#x000a0;the treatment during the regimen.<xref ref-type="bibr" rid="article-21383.r1">[1]</xref>&#x000a0;Hepatotoxicity is a common adverse effect of antitubercular treatments. Hence, both baseline and periodic hepatic function require assessment. Patients receiving iron overload may need prolonged treatment or added bactericidal drugs to their regimen. One study showed that iron loading negatively affected the bactericidal properties of INH and ethambutol. The excess iron limits the bactericidal effects of INH and completely inhibits that of ethambutol. Although this study focused on murine tuberculosis, clinical implications&#x000a0;for HIV-positive patients with lower CD4+ cells may exist but may also have certain degrees of iron loading or patients with haptoglobin 2-2 genotype. Due to the adverse effects of excess iron, patients who have these conditions may need to consider a more prolonged treatment or add bactericidal drugs to their regimen against tuberculosis.<xref ref-type="bibr" rid="article-21383.r20">[20]</xref></p>
      </sec>
      <sec id="article-21383.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Toxicity</bold>
</p>
        <p>One of the most well-known adverse effects is optic neuritis. The effect of neuritis is dose-related, with greater than 40% of adults developing toxicity at doses greater than 50 mg/kg and around 0% to 3% of adults developing toxicity at 15 mg/kg/daily.<xref ref-type="bibr" rid="article-21383.r21">[21]</xref>&#x000a0;Currently, unknown protocols detect subclinical ethambutol-induced ocular toxicity. The results of a study in Korea conducted various visual tests such as color vision tests, retinal nerve fiber layer optical coherence tomography tests, and pattern visual evoked potential tests. The&#x000a0;results showed that&#x000a0;retinal nerve fiber layer optical coherence tomography tests and pattern&#x000a0;visual evoked potential tests&#x000a0;were promising as they could detect changes in visual patterns after&#x000a0;6 months, while other tests in visual acuity, color vision, or visual fields showed no significant changes.<xref ref-type="bibr" rid="article-21383.r22">[22]</xref></p>
        <p>
<bold>Management of Toxicity</bold>
</p>
        <p>The manifestation of ethambutol-induced optic neuropathy appears to be from&#x000a0;the chelation of copper. A study with 60 patients undergoing treatment with ethambutol monitored their serum copper levels. Statistical analysis confirmed a significant change in copper concentration, supporting the copper chelation effect.<xref ref-type="bibr" rid="article-21383.r23">[23]</xref>&#x000a0;An in-vitro study suggests that therapeutic copper can potentially prevent ethambutol-induced optic neuropathy while not compromising&#x000a0;the bacteriostatic properties.<xref ref-type="bibr" rid="article-21383.r24">[24]</xref>&#x000a0;Patients who experience any visual symptoms should discontinue the drug immediately and consult their doctor.<xref ref-type="bibr" rid="article-21383.r25">[25]</xref></p>
      </sec>
      <sec id="article-21383.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ethambutol-induced optic neuropathy is a well-known disease that can be irreversible but is preventable. Timely and appropriate screenings are important in determining the outcome of the patient.&#x000a0;According to epidemiologic studies investigating this neuropathy, between 0.7% and 1.29% of patients showed a prevalence of optic neuropathy when taking the World Health Organization recommended dosages. Optical coherence tomography&#x000a0;demonstrated a clinically significant decrease in the thickness of the retinal nerve fiber layer.<xref ref-type="bibr" rid="article-21383.r26">[26]</xref>&#x000a0;Ethambutol-induced optic neuropathy is a well-known adverse effect of treatment; all patients on ethambutol should be screened regularly by ophthalmologists.<xref ref-type="bibr" rid="article-21383.r25">[25]</xref>&#x000a0;Although ethambutol&#x000a0;is a bacteriostatic agent used to prevent the emergence of drug resistance to other first-line drugs, ethambutol-resistant strains are recognized.&#x000a0;With the rise of drug-resistant strains of TB and the current 6-month regimen of&#x000a0;4 drugs that can potentially expand to 18&#x000a0;to 24 months, leading to inadequate compliance and poor outcomes, a search for different treatments persists. Completion of and compliance with the anti-tuberculosis regimen are paramount to treating TB patients and controlling TB globally.<xref ref-type="bibr" rid="article-21383.r27">[27]</xref> The development of new drugs such as bedaquiline, pretomanid, delamanid, and bedaquiline&#x000a0;to combat these challenges can significantly impact how tuberculosis is treated and transmitted.<xref ref-type="bibr" rid="article-21383.r5">[5]</xref><xref ref-type="bibr" rid="article-21383.r28">[28]</xref>&#x000a0;</p>
        <p>Pharmacies are crucial in&#x000a0;TB control, especially in high-burden countries. However, they often face challenges in providing quality care, including the availability of anti-TB drugs and patient management. Interventions, such as public-private mix initiatives, aim to improve case detection by training pharmacists to refer symptomatic patients for testing. Ethambutol, a key anti-TB drug, is often stocked, but quality assurance is essential. Future efforts should focus on expanding interventions to improve patient counseling and address inappropriate medication sales while establishing global pharmacy-specific guidelines and enhancing regulatory environments.<xref ref-type="bibr" rid="article-21383.r29">[29]</xref>&#x000a0;Given ethambutol's toxicity profile, the decision to&#x000a0;treat tuberculosis cases should involve an interprofessional team, including infectious disease specialists. Close monitoring of the patient, careful assessment of the medication profile, and determining the susceptibility of the infection are all key factors in charting the therapeutic course. An interprofessional team approach and open communication between infectious disease specialists, nurse practitioners, physician assistants, pharmacists, and ophthalmologists are necessary to&#x000a0;optimize patient outcomes with&#x000a0;ethambutol therapy.</p>
      </sec>
      <sec id="article-21383.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21383&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21383">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21383/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21383">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21383.s11">
        <title>References</title>
        <ref id="article-21383.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol-associated optic neuropathy.</article-title>
            <source>Ann Acad Med Singap</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <page-range>274-8</page-range>
            <pub-id pub-id-type="pmid">16710500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Alipanah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lienhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrifield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saukkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>e147</fpage>
            <page-range>e147-e195</page-range>
            <pub-id pub-id-type="pmid">27516382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Iaccarino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cambau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Andrejak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttger</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huitt</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Leitman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marras</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Santin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tortoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Ingen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Winthrop</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Aug</month>
            <day>14</day>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e36</page-range>
            <pub-id pub-id-type="pmid">32628747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaushik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Subudhi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sikdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ranjan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tc-99m Ethambutol Scintigraphy with Single-Photon Emission Computed Tomography in Diagnosis of Tubercular Iliopsoas Abscess.</article-title>
            <source>Indian J Nucl Med</source>
            <year>2023</year>
            <season>Oct-Dec</season>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-391</page-range>
            <pub-id pub-id-type="pmid">38390540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palomino</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug Resistance Mechanisms in Mycobacterium tuberculosis.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2014</year>
            <month>Jul</month>
            <day>02</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-40</page-range>
            <pub-id pub-id-type="pmid">27025748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schubert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sieger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giacomelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rieblinger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindenthal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bramkamp</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria.</article-title>
            <source>mBio</source>
            <year>2017</year>
            <month>Feb</month>
            <day>07</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28174310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>ZG</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanism of the synergistic activity of ethambutol and isoniazid against <italic>Mycobacterium tuberculosis</italic>.</article-title>
            <source>J Biol Chem</source>
            <year>2018</year>
            <month>Oct</month>
            <day>26</day>
            <volume>293</volume>
            <issue>43</issue>
            <fpage>16741</fpage>
            <page-range>16741-16750</page-range>
            <pub-id pub-id-type="pmid">30185616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tikiso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McIlleron</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abdelwahab</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bekker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hesseling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chabala</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zar</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Rabie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andrieux-Meyer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Denti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of ethambutol in African children: a pooled analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2022</year>
            <month>Jun</month>
            <day>29</day>
            <volume>77</volume>
            <issue>7</issue>
            <fpage>1949</fpage>
            <page-range>1949-1959</page-range>
            <pub-id pub-id-type="pmid">35466379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiberi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Utjesanovic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galvin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Centis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Ambrosio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van den Boom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zumla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Drug resistant TB - latest developments in epidemiology, diagnostics and management.</article-title>
            <source>Int J Infect Dis</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>124 Suppl 1</volume>
            <fpage>S20</fpage>
            <page-range>S20-S25</page-range>
            <pub-id pub-id-type="pmid">35342000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.</article-title>
            <source>J Korean Med Sci</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">25653488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouffard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nathavitharana</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Yassa</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Torun</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Re-Treatment With Ethambutol After Toxic Optic Neuropathy.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-42</page-range>
            <pub-id pub-id-type="pmid">27636749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mokhtarzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panahi-Azar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamishehkar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mesgari-Abbasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ezzati Nazhad Dolatabadi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de la Guardia</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.</article-title>
            <source>AAPS PharmSciTech</source>
            <year>2019</year>
            <month>Feb</month>
            <day>22</day>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>120</fpage>
            <pub-id pub-id-type="pmid">30796625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bobrowitz</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol in pregnancy.</article-title>
            <source>Chest</source>
            <year>1974</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-4</page-range>
            <pub-id pub-id-type="pmid">4843599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Ethambutol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geyer</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Herskovitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Slamovits</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Schaumburg</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-8</page-range>
            <pub-id pub-id-type="pmid">24897009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Antitubercular drug-induced violent suicide of a hospitalised patient.</article-title>
            <source>BMJ Case Rep</source>
            <year>2014</year>
            <month>Jan</month>
            <day>06</day>
            <volume>2014</volume>
            <pub-id pub-id-type="pmid">24395874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bulpitt</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jaresko</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jelliffe</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nix</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>568</fpage>
            <page-range>568-72</page-range>
            <pub-id pub-id-type="pmid">10049268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Interactive effect of oral anti-hyperglycaemic or anti-hypertensive drugs on the inhibitory and bactericidal activity of first line anti-TB drugs against M. tuberculosis.</article-title>
            <source>PLoS One</source>
            <year>2023</year>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>e0292397</fpage>
            <pub-id pub-id-type="pmid">38032920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-8</page-range>
            <pub-id pub-id-type="pmid">26459901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lounis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maslo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Truffot-Pernot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grosset</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boelaert</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>575</fpage>
            <page-range>575-9</page-range>
            <pub-id pub-id-type="pmid">12797701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donald</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maritz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Qazi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol dosage for the treatment of children: literature review and recommendations.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1318</fpage>
            <page-range>1318-30</page-range>
            <pub-id pub-id-type="pmid">17167947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level.</article-title>
            <source>Cutan Ocul Toxicol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>228</fpage>
            <page-range>228-32</page-range>
            <pub-id pub-id-type="pmid">26361935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbasi Nazari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobarfard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tabarsi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salamzadeh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Serum copper (cu) alterations in pulmonary tuberculosis patients under treatment with ethambutol.</article-title>
            <source>Biol Trace Elem Res</source>
            <year>2009</year>
            <month>May</month>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-6</page-range>
            <pub-id pub-id-type="pmid">19002388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kozak</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Inderlied</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Sadun</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-7</page-range>
            <pub-id pub-id-type="pmid">9554173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phuljhele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalaiselvan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Karna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lodha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>3734</fpage>
            <page-range>3734-3739</page-range>
            <pub-id pub-id-type="pmid">34827033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlain</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Sadaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol optic neuropathy.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-551</page-range>
            <pub-id pub-id-type="pmid">28759559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valencia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Losada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sequera</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Quevedo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Basteiro</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>How do we measure adherence to anti-tuberculosis treatment?</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-165</page-range>
            <pub-id pub-id-type="pmid">27910715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schechter</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ashkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Peter Cegielski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrino</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Burgos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caloia</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colon-Semidey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeSilva</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dhanireddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dorman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dworkin</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Hammond-Epstein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Gaensbauer</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ghassemieh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jasuja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kracen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Labuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lardizabal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lasley</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Letzer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Lubelchek</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Patricia Macias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mihalyov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Misch</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nilsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ninneman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oladele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Overman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ritger</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Rowlinson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sabuwala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Spitters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Tresgallo</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Valois</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goswami</surname>
                <given-names>ND</given-names>
              </name>
              <collab>BPaL Implementation Group</collab>
            </person-group>
            <article-title>Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.</article-title>
            <source>Clin Infect Dis</source>
            <year>2023</year>
            <month>Oct</month>
            <day>05</day>
            <volume>77</volume>
            <issue>7</issue>
            <fpage>1053</fpage>
            <page-range>1053-1062</page-range>
            <pub-id pub-id-type="pmid">37249079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21383.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Quality of tuberculosis care by pharmacies in low- and middle-income countries: Gaps and opportunities.</article-title>
            <source>J Clin Tuberc Other Mycobact Dis</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>18</volume>
            <fpage>100135</fpage>
            <pub-id pub-id-type="pmid">31872080</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
